SCHEDULE: Paradigm BioCapital Reduces Stake in LENZ Therapeutics Below 5%

Paradigm BioCapital Advisors LP and its affiliates have reduced their beneficial ownership in LENZ Therapeutics, Inc. to below the 5% threshold, as disclosed in an amended Schedule 13G filing.

Summary

• Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. each beneficially own 1,073,461 shares of LENZ Therapeutics, Inc. Common Stock, representing 3.8% of the class.
• Paradigm BioCapital International Fund Ltd. beneficially owns 946,447 shares, representing 3.3% of the class.
• The beneficial ownership percentages are calculated based on 28,588,261 shares of Common Stock outstanding as of September 30, 2025.
• This filing is an Amendment No. 1 to a Schedule 13G, indicating a reduction in beneficial ownership from a previous filing where the reporting persons held 5% or more.
• The reporting persons explicitly state their ownership is now 5 percent or less of the class.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant institutional investor reducing its stake below the 5% reporting threshold, implying a partial divestment and potentially reduced confidence in the issuer.

Negatives

• Paradigm BioCapital entities have reduced their beneficial ownership in LENZ Therapeutics, Inc. to below 5% (3.8% and 3.3% respectively), indicating a divestment of a portion of their holdings.

Risks

• A reduction in significant institutional ownership could signal a lack of confidence from a major investor, potentially impacting market perception and share price.

Future Outlook

This filing does not contain any forward-looking statements or guidance from LENZ Therapeutics, Inc. or the reporting persons regarding the issuer's future performance.

Industry Context

This filing reflects a change in institutional investor positioning within the biotechnology or pharmaceutical sector, specifically concerning LENZ Therapeutics, Inc., a company focused on therapeutic development. A reduction in a significant stake by a specialized biotech investor like Paradigm BioCapital could be observed by other investors in the sector.

Stakeholder Impact

• Shareholders may interpret the reduction in institutional ownership as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Potential investors might view this divestment as a reason to reconsider or reduce their own investment in LENZ Therapeutics, Inc.

Key Dates

Recommendation

The reduction in a significant institutional stake by Paradigm BioCapital suggests a potential loss of confidence or a strategic reallocation of capital. While not an outright 'sell' signal without further context on the investor's rationale or the company's fundamentals, it warrants a 'hold' recommendation for existing investors to re-evaluate their position and for potential investors to exercise caution and conduct deeper due diligence before initiating a position.

Keywords

LENZ Therapeutics, Paradigm BioCapital, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Equity Stake, Divestment